Tafasitamab in DLBCL
An interview with Lymphoma Hub Chair Gilles Salles on the use of tafasitamab in patients with diffuse large B cell lymphoma (DLBCL).
FDA grants priority review for crizotinib in pediatric ALK-positive R/R ALCL
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application for crizotinib, for use in pediatric patients...
" The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology. "